Michael E. Weinblatt

54.2k total citations · 10 hit papers
381 papers, 33.9k citations indexed

About

Michael E. Weinblatt is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Michael E. Weinblatt has authored 381 papers receiving a total of 33.9k indexed citations (citations by other indexed papers that have themselves been cited), including 281 papers in Rheumatology, 99 papers in Genetics and 98 papers in Hematology. Recurrent topics in Michael E. Weinblatt's work include Rheumatoid Arthritis Research and Therapies (252 papers), Systemic Lupus Erythematosus Research (102 papers) and Chronic Lymphocytic Leukemia Research (96 papers). Michael E. Weinblatt is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (252 papers), Systemic Lupus Erythematosus Research (102 papers) and Chronic Lymphocytic Leukemia Research (96 papers). Michael E. Weinblatt collaborates with scholars based in United States, United Kingdom and Canada. Michael E. Weinblatt's co-authors include Nancy A. Shadick, Robert M. Plenge, David Reich, Alkes L. Price, David M. Lee, Joel M. Kremer, Daniel E. Fürst, Edward Keystone, Roy Fleischmann and H. James Williams and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Michael E. Weinblatt

368 papers receiving 32.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Principal components analysis corrects for stratification in genome-wide association studies

2006 6.4k citations Michael E. Weinblatt, Nancy A. Shadick et al. profile →
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

1995 2.2k citations David T. Felson, Vibeke Strand et al. profile →
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

1999 1.6k citations Michael E. Weinblatt, Joel M. Kremer et al. profile →
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 1.4k citations Michael E. Weinblatt, Daniel E. Furst et al. profile →
The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

1993 1.3k citations David T. Felson, Michael E. Weinblatt et al. profile →
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

1998 1.2k citations Michael E. Weinblatt et al. profile →
Rheumatoid arthritis

2001 1.0k citations Michael E. Weinblatt et al. profile →
Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production

2010 860 citations Éric Boilard, Peter A. Nigrović et al. Science profile →
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis

1985 705 citations Michael E. Weinblatt et al. profile →
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

2017 621 citations Peter C. Taylor, Désirée van der Heijde et al. profile →

Peers

Countries citing papers authored by Michael E. Weinblatt

Since Specialization

Citations

This map shows the geographic impact of Michael E. Weinblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Weinblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Weinblatt more than expected).

Fields of papers citing papers by Michael E. Weinblatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Weinblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Weinblatt. The network helps show where Michael E. Weinblatt may publish in the future.

Co-authorship network of co-authors of Michael E. Weinblatt

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Weinblatt. A scholar is included among the top collaborators of Michael E. Weinblatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Weinblatt. Michael E. Weinblatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characteristics Associated With Detectable High‐Sensitivity Cardiac Troponin in Patients With Rheumatoid Arthritis at Low‐Intermediate Cardiac Risk 2025 ·ACR Open Rheumatology ·Ilana M. Usiskin, (unknown), Ying Qi, Nancy A. Shadick, Michael E. Weinblatt, Brittany Weber, Katherine P. Liao	0
2	Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X) 2025 ·BMJ Open ·Michael E. Weinblatt, Peter C. Taylor, Iain B. McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David P. Brooks, Paula Curtis, Anubha Gupta, R. Nijhawan, (unknown), Katey J. Rayner, (unknown), (unknown), Millie Wang, (unknown), Roy Fleischmann	1
3	Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis 2024 ·Seminars in Arthritis and Rheumatism ·Gregory C McDermott, Michael DiIorio, Yumeko Kawano, (unknown), (unknown), (unknown), Su‐Jin Moon, (unknown), Jonathan S. Coblyn, Elena Massarotti, Michael E. Weinblatt, Dana Weisenfeld, Katherine P. Liao	4
4	P106 Do high rheumatoid factor titres impact response to tumour necrosis factor inhibitors? Comparison of certolizumab pegol and adalimumab in patients with rheumatoid arthritis and high titres of rheumatoid factor: a post hoc analysis of a phase 4 trial. 2024 ·Lara D. Veeken ·Josef S Smolen, Peter C. Taylor, Yoshiya Tanaka, (unknown), Bernard Lauwerys, Ricardo Machado Xavier, Jeffrey R. Curtis, Ted R. Mikuls, Michael E. Weinblatt	1
5	Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis 2024 ·Lara D. Veeken ·Josef S Smolen, Peter C. Taylor, Yoshiya Tanaka, Tsutomu Takeuchi, Motomu Hashimoto, (unknown), Bernard Lauwerys, Nicola Tilt, (unknown), Ricardo Machado Xavier, Alejandro Balsa, Jeffrey R. Curtis, Ted R. Mikuls, Michael E. Weinblatt	6
6	Understanding Differences in Patient Descriptions of Rheumatoid Arthritis Flares Using OMERACT Core Domains 2023 ·The Journal of Rheumatology ·(unknown), Christine Iannaccone, (unknown), Michelle Frits, Vivian P. Bykerk, Clifton O. Bingham, Michael E. Weinblatt, Nancy A. Shadick	2
7	A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings 2023 ·ACR Open Rheumatology ·(unknown), Kenneth G. Saag, (unknown), K. Obermeyer, (unknown), Brian LaMoreaux, Lissa Padnick‐Silver, (unknown), (unknown), (unknown), John Tesser, Michael E. Weinblatt	13
8	Meaning of patient global assessment when joint counts are low in rheumatoid arthritis 2022 ·RMD Open ·David T. Felson, (unknown), (unknown), Daniel H. Solomon, Michael E. Weinblatt, Nancy A. Shadick	2
9	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 2 2020 ·Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	42
10	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1 2020 ·Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, (unknown), Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	97
11	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3 2020 ·Arthritis & Rheumatology ·Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen H. Costenbader, Ellen M. Gravallese, André C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy S. Turner, Kenneth G. Saag	145
12	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach 2019 ·ACR Open Rheumatology ·Candace H. Feldman, Kazuki Yoshida, Chang Xu, Michelle Frits, Nancy A. Shadick, Michael E. Weinblatt, Seán Connolly, E. Alemao, Daniel H. Solomon	10
13	The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study 2019 ·ACR Open Rheumatology ·Nancy A. Shadick, Patricia Katz, (unknown), (unknown), Jonathan S. Coblyn, Michael E. Weinblatt, Jing Cui	10
14	Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody 2018 ·Arthritis & Rheumatology ·Gerd R Burmester, Iain B. McInnes, Joel M. Kremer, Pedro C. Miranda, Jiří Vencovský, A. Godwood, (unknown), (unknown), Xiang Guo, D. Close, Michael E. Weinblatt	62
15	Mixed-effects association of single cells identifies an expanded effector CD4 ⁺ T cell subset in rheumatoid arthritis 2018 ·Science Translational Medicine ·Chamith Y. Fonseka, Deepak A. Rao, Nikola C. Teslovich, Ilya Korsunsky, Susan Hannes, Kamil Slowikowski, Michael F. Gurish, Laura T. Donlin, Eddie A. James, Michael E. Weinblatt, Elena Massarotti, Jonathan S. Coblyn, Simon M. Helfgott, Derrick J. Todd, Vivian P. Bykerk, Elizabeth W. Karlson, Joerg Ermann, Yvonne Lee, Michael B. Brenner, Soumya Raychaudhuri	99
16	A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis 2017 ·Arthritis & Rheumatology ·Michael E. Weinblatt, Iain B. McInnes, Joel M. Kremer, Pedro C. Miranda, Jiří Vencovský, Xiang Guo, Wendy I. White, Patricia C. Ryan, A. Godwood, (unknown), D. Close, Gerd R Burmester	72
17	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study 2016 ·Annals of the Rheumatic Diseases ·Paul Emery, Clifton O. Bingham, Gerd R Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Catherine Arendt, Irina Mountian, O. Purcaru, Daljit Tatla, Michael E. Weinblatt, (unknown)	72
18	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study 2015 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Michael E. Weinblatt, Désirée van der Heijde, William F. C. Rigby, Ronald van Vollenhoven, Clifton O. Bingham, Melissa Veenhuizen, Anne Gill, Fangyi Zhao, Wendy Komocsar, (unknown), Robert Ortmann, Chin Lee	27
19	Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure 2011 ·Research Explorer (The University of Manchester) ·Arthur Kavanaugh, Michael E. Weinblatt, Mark C. Genovese, (unknown), Elliott B. Grossbard, Daniel B. Magilavy, Sally Hollis	7
20	Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production breakdown → 2010 ·Science ·Éric Boilard, Peter A. Nigrović, Katherine Larabee, Gerald F. Watts, Jonathan S. Coblyn, Michael E. Weinblatt, Elena Massarotti, Eileen Remold‐O’Donnell, Richard W. Farndale, Jerry Ware, David Lee	860

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact